Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
F 37.55 -0.24% -0.09
GLPG closed down 0.24 percent on Friday, March 24, 2023, on 48 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Gapped Down Weakness 0.00%
20 DMA Resistance Bearish -0.24%
Spinning Top Other -0.24%
Bollinger Band Squeeze Range Contraction -0.24%
Inside Day Range Contraction -0.24%
Gapped Up Strength -0.24%
Fell Below 20 DMA Bearish 0.45%
Bollinger Band Squeeze Range Contraction 0.45%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Galapagos NV Description

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Acid Clinical Development Autoimmune Disease Inflammation Monoclonal Antibodies Inflammatory Diseases Rheumatoid Arthritis Inflammatory Bowel Disease Psoriasis Ulcer Ulcerative Colitis Colitis Cystic Fibrosis Osteoarthritis Abdominal Pain Fatty Acids Arthritis Janus Kinase Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Morphosys Treatment Of Inflammation

Is GLPG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 72.11
52 Week Low 36.2
Average Volume 298,338
200-Day Moving Average 45.86
50-Day Moving Average 40.93
20-Day Moving Average 37.80
10-Day Moving Average 38.35
Average True Range 0.88
RSI 40.48
ADX 25.09
+DI 19.12
-DI 34.36
Chandelier Exit (Long, 3 ATRs) 37.06
Chandelier Exit (Short, 3 ATRs) 38.85
Upper Bollinger Bands 39.35
Lower Bollinger Band 36.26
Percent B (%b) 0.42
BandWidth 8.17
MACD Line -0.65
MACD Signal Line -0.79
MACD Histogram 0.1397
Fundamentals Value
Market Cap 2.45 Billion
Num Shares 65.3 Million
EPS -1.69
Price-to-Earnings (P/E) Ratio -22.27
Price-to-Sales 14.69
Price-to-Book 2.45
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.44
Resistance 3 (R3) 38.37 38.00 38.29
Resistance 2 (R2) 38.00 37.78 38.04 38.24
Resistance 1 (R1) 37.78 37.64 37.89 37.85 38.19
Pivot Point 37.41 37.41 37.47 37.44 37.41
Support 1 (S1) 37.18 37.18 37.30 37.25 36.91
Support 2 (S2) 36.81 37.04 36.85 36.86
Support 3 (S3) 36.59 36.81 36.81
Support 4 (S4) 36.66